News Pressroom

September 16, 2005

MedImmune's General Counsel Named a 'Top Washington Lawyer'

Washington Business Journal Recognizes William Bertrand for Work as Corporate Counsel

GAITHERSBURG, Md., Sept. 16 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI) announced today that the Washington Business Journal has recognized William Bertrand, J.D. as one of the region's best lawyers at its second annual "Top Washington Lawyers" awards reception held yesterday in Washington, DC. Mr. Bertrand is the vice president, general counsel, corporate secretary and corporate compliance officer at MedImmune.

The "Top Washington Lawyers" award honors local lawyers in fourteen categories. The publication received more than 350 nominations. Mr. Bertrand won the award in the category of General Counsel and was honored for his work ethic and dedication to his profession. He was also recognized for his contributions as an invaluable resource to the company and its daily operations. This is the second recognition of MedImmune's senior management by the publication. In December 2004, the Washington Business Journal honored MedImmune's Lota Zoth, chief financial officer, as a "Woman Who Means Business."

"We are proud that the Washington Business Journal has once again recognized an outstanding MedImmune leader," said David M. Mott, chief executive officer. "Bill's high integrity and innovative, entrepreneurial spirit make him a deserving recipient of this award. He is a dedicated and driven employee, an outstanding leader and a role model to those who work with him."

Mr. Bertrand joined MedImmune in November 2001. Since then, he has held the titles of vice president, legal affairs; general counsel; corporate secretary; and, corporate compliance officer. Under Mr. Bertrand's leadership, MedImmune's legal affairs department has flourished from only four members in 2001 to more than 20 members in 2005, including more than 10 full- time attorneys. Over the past four years, he has established a number of programs and processes designed to protect and improve MedImmune's business and its work practices.

Mr. Bertrand is a Michigan native who holds a bachelor of science degree in biology from Wayne State University and a juris doctorate (cum laude) from the University of Wisconsin - Madison. Prior to joining MedImmune, Mr. Bertrand served in various legal positions at Pharmacia Corporation from 1997- 2001, including litigation counsel, senior corporate counsel and associate general counsel. He had also been associate general counsel for a life insurance company; a partner at Dickinson, Wright, Moon, Van Dusen & Freeman of Lansing, MI; and taught courses at various institutions, including Seton Hall University School of Law.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 2,000 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

SOURCE MedImmune, Inc.

CONTACT:
Media:
Jamie Lacey, +1-301-398-4035
Investors:
John Filler, +1-301-398-4086
both of MedImmune, Inc.